Health care resource use and costs among patients with cushing disease

Endocrine Practice

Volumn 17, Issue 5, 2011, Pages 681-690

  Swearingen, Brooke ^a   Wu, Ning ^b   Chen, Shih Yin ^b   Pulgar, Sonia ^c   Biller, Beverly M K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNITED BIOSOURCE CORPORATION   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; CUSHING DISEASE; DIABETES MELLITUS; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPOPHYSIS ADENOMA; MAJOR CLINICAL STUDY; MALE; REMISSION; RETROSPECTIVE STUDY;

EID: 80054079890     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP10368.OR     Document Type: Article

References (70)

1. Azziz R. The evaluation and management of hirsutism. Obstet Gynecol. 2003;101:995-1007.
2. Martin KA, Chang RJ, Ehrmann DA, et al. Evaluation and treatment of hirsutism in premenopausal women: An endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008;93:1105-1120.
3. Lee HJ, Ha SJ, Lee JH, Kim JW, Kim HO, Whiting DA. Hair counts from scalp biopsy specimens in Asians. J Am Acad Dermatol. 2002;46:218-221.
4. Deplewski D, Rosenfield RL. Role of hormones in pilose-baceous unit development. Endocr Rev. 2000;21:363-392.
5. Alonso LC, Rosenfield RL. Molecular genetic and endo-crine mechanisms of hair growth. Horm Res. 2003;60:1-13.
6. Rosenfield RL. Clinical practice. Hirsutism. N Engl J Med. 2005;353:2578-2588.
7. Lookingbill DP, Demers LM, Wang C, Leung A, Rittmaster RS, Santen RJ. Clinical and biochemi-cal parameters of androgen action in normal healthy Caucasian versus Chinese subjects. J Clin Endocrinol Metab. 1991;72:1242-1248.
8. Azziz R, Carmina E, Sawaya ME. Idiopathic hirsutism. Endocr Rev. 2000;21:347-362.
9. Randall VA, Ebling FJ. Seasonal changes in human hair growth. Br J Dermatol. 1991;124:146-151.
10. Plymate SR, Hoop RC, Jones RE, Matej LA. Regulation of sex hormone-binding globulin production by growth factors. Metabolism. 1990;39:967-970.
11. Carmina E, Rosato F, Jannì A, Rizzo M, Longo RA. Extensive clinical experience: Relative prevalence of dif-ferent androgen excess disorders in 950 women referred because of clinical hyperandrogenism. J Clin Endocrinol Metab. 2006;91:2-6.
12. Azziz R, Sanchez LA, Knochenhauer ES, et al. Androgen excess in women: Experience with over 1000 consecutive patients. J Clin Endocrinol Metab. 2004;89:453-462.
13. Azziz R, Carmina E, Dewailly D, et al; Task Force on the Phenotype of the Polycystic Ovary Syndrome of The Androgen Excess and PCOS Society. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: The complete task force report. Fertil Steril. 2009;91:456-488.
14. Sam S, Dunaif A. Polycystic ovary syndrome: Syndrome XX? Trends Endocrinol Metab. 2003;14:365-370.
15. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. 2005;352:1223-1236.
16. Dunaif A. Insulin resistance and the polycystic ovary syndrome: Mechanism and implications for pathogenesis. Endocr Rev. 1997;18:774-800.
17. Moran L, Teede H. Metabolic features of the reproductive phenotypes of polycystic ovary syndrome. Hum Reprod Update. 2009;15:477-488.
18. Practice Committee of the American Society for Reproductive Medicine. The evaluation and treat-ment of androgen excess. Fertil Steril. 2006;86(5 Suppl 1):S241-S247.
19. Johnstone EB, Rosen MP, Neril R, et al. The polycystic ovary post-Rotterdam: A common, age-dependent finding in ovulatory women without metabolic significance. J Clin Endocrinol Metab. 2010;95:4965-4972.
20. Ehrmann DA, Liljenquist DR, Kasza K, Azziz R, Legro RS, Ghazzi MN; PCOS/Troglitazone Study Group. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91:48-53.
21. Balen AH, Conway GS, Kaltsas G, et al. Polycystic ovary syndrome: The spectrum of the disorder in 1741 patients. Hum Reprod. 1995;10:2107-1211.
22. Pall M, Azziz R, Beires J, Pignatelli D. The phenotype of hirsute women: A comparison of polycystic ovary syn-drome and 21-hydroxylase-deficient nonclassic adrenal hyperplasia. Fertil Steril. 2010;94:684-689.
23. Semple RK, Savage DB, Cochran EK, Gorden P, O'Rahilly S. Genetic syndromes of severe insulin resis-tance. Endocr Rev. 2011;32:498-514.
24. Speiser PW, Azziz R, Baskin LS, et al; Endocrine Society. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: An Endocrine Society clini-cal practice guideline [Erratum in J Clin Endocrinol Metab. 2010;95:5137]. J Clin Endocrinol Metab. 2010;95: 4133-4160.
25. Erratum in J Clin Endocrinol Metab. 2010;95:5137
26. New MI. Extensive clinical experience: Nonclassical 21-hydroxylase deficiency J Clin Endocrinol Metab. 2006;91: 4205-4214.
27. [Erratum in J Clin Endocrinol Metab. 2007;92:142]
28. Nieman LK, Biller BM, Findling JW, et al. The diag-nosis of Cushing's syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2008;93:1526-1540.
29. Weekly clinicopathological exercises. Case 22-1988. A 13-year-old girl with secondary amenorrhea, obesity, acanthosis nigricans, and hirsutism. N Engl J Med. 1988; 318:1449-1457.
30. Koulouri O, Conway GS. Management of hirsutism. BMJ. 2009;338:b847.
31. Danilowicz K, Albiger N, Vanegas M, Gómez RM, Cross G, Bruno OD. Androgen-secreting adrenal adenomas. Obstet Gynecol. 2002;100(5 Pt 2):1099-1102.
32. Vilar L, Freitas MC, Naves LA, et al. Diagnosis and management of hyperprolactinemia: Results of a Brazilian multicenter study with 1234 patients. J Endocrinol Invest. 2008;31:436-444.
33. Kaltsas GA, Mukherjee JJ, Jenkins PJ, et al. Menstrual irregularity in women with acromegaly. J Clin Endocrinol Metab. 1999;84:2731-2735.
34. Unluhizarci K, Gokce C, Atmaca H, Bayram F, Kelestimur F. A detailed investigation of hirsutism in a Turkish population: Idiopathic hyperandrogenemia as a perplexing issue. Exp Clin Endocrinol Diabetes. 2004;112: 504-509.
35. Souter I, Sanchez LA, Perez M, Bartolucci AA, Azziz R. The prevalence of androgen excess among patients with minimal unwanted hair growth. Am J Obstet Gynecol. 2004;191:1914-1920.
36. Glintborg D, Henriksen JE, Andersen M, et al. Prevalence of endocrine diseases and abnormal glucose tol-erance tests in 340 Caucasian premenopausal women with hirsutism as the referral diagnosis. Fertil Steril. 2004;82: 1570-1579.
37. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab. 1961;21: 1440-1447.
38. Yildiz BO, Bolour S, Woods K, Moore A, Azziz R. Visually scoring hirsutism. Hum Reprod Update. 2010;16:51-64.
39. Kim JJ, Chae SJ, Choi YM, et al. Assessment of hirsut-ism among Korean women: Results of a randomly selected sample of women seeking pre-employment physical check-up. Hum Reprod. 2011;26:214-220.
40. Cheewadhanaraks S, Peeyananjarassri K, Choksuchat C. Clinical diagnosis of hirsutism in Thai women. J Med Assoc Thai. 2004;87:459-463.
41. Vermeulen A, Verdonck L, Kaufman JM. A criti-cal evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999;84:3666-3672.
42. Rosner W, Vesper H, Endocrine Society, et al. Toward excellence in testosterone testing: A consensus statement. J Clin Endocrinol Metab. 2010;95:4542-4548.
43. Legro RS, Schlaff WD, Diamond MP, et al; Reproductive Medicine Network. Total testosterone assays in women with polycystic ovary syndrome: Preci-sion and correlation with hirsutism. J Clin Endocrinol Metab. 2010;95:5305-5313.
44. Kaltsas GA, Mukherjee JJ, Kola B, et al. Is ovarian and adrenal venous catheterization and sampling helpful in the investigation of hyperandrogenic women? Clin Endocrinol (Oxf). 2003;59:34-43.
45. Mattsson C, Stanhope CR, Sam S, Young WF Jr. Image in endocrinology: Testosterone-secreting ovarian tumor local-ized with (fluorine-18)-2- deoxyglucose positron emission tomography. J Clin Endocrinol Metab. 2006;91:738-739.
46. Goodman NF, Bledsoe MB, Cobin RH, et al; American Association of Clinical Endocrinologists Hyperandrogenic Disorders Task Force. American Association of Clinical Endocrinologists medical guide-lines for the clinical practice for the diagnosis and treat-ment of hyperandrogenic disorders. Endocr Pract. 2001;7: 120-134.
47. Wild RA, Umstot ES, Andersen RN, Ranney GB, Givens JR. Androgen parameters and their correlation with body weight in one hundred thirty-eight women thought to have hyperandrogenism. Am J Obstet Gynecol. 1983;146:602-606.
48. Azziz R, Carmina E, Dewailly D, et al. Positions state-ment: Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: An Androgen Excess Society guideline. J Clin Endocrinol Metab. 2006; 91:4237-4245.
49. Franks S. Polycystic ovary syndrome in adolescents. Int J Obes (Lond). 2008;32:1035-1041.
50. Legro RS, Driscoll D, Strauss JF 3rd, Fox J, Dunaif A. Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci U S A. 1998;95:14956-14960.
51. Petitti DB. Clinical practice. Combination estrogen-proges-tin oral contraceptives. N Engl J Med. 2003;349:1443-1450.
52. Breitkopf DM, Rosen MP, Young SL, Nagamani M. Efficacy of second versus third generation oral contracep-tives in the treatment of hirsutism. Contraception. 2003; 67:349-353.
53. Knopp RH, Broyles FE, Cheung M, Moore K, Marcovina S, Chandler WL. Comparison of the lipoprotein, carbohydrate, and hemostatic effects of pha-sic oral contraceptives containing desogestrel or levonorg-estrel. Contraception. 2001;63:1-11.
54. Practice Committee of the American Society for Reproductive Medicine. Hormonal contraception: Recent advances and controversies. Fertil Steril. 2008;90(Suppl 5):S103-S113.
55. Gomes MP, Deitcher SR. Risk of venous thromboembolic disease associated with hormonal contraceptives and hor-mone replacement therapy: A clinical review. Arch Intern Med. 2004;164:1965-1976.
56. Carmina E, Lobo RA. Peripheral androgen blockade ver-sus glandular androgen suppression in the treatment of hir-sutism. Obstet Gynecol. 1991;78(5 Pt 1):845-849.
57. Spritzer P, Billaud L, Thalabard JC, et al. Cyproterone acetate versus hydrocortisone treatment in late-onset adre-nal hyperplasia. J Clin Endocrinol Metab. 1990;70:642-646.
58. Dunaif A. Drug insight: Insulin-sensitizing drugs in the treatment of polycystic ovary syndrome-A reappraisal. Nat Clin Pract Endocrinol Metab. 2008;4:272-283.
59. Azziz R, Ehrmann D, Legro RS, et al. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: A multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab. 2001;86:1626-1632.
60. Swiglo BA, Cosma M, Flynn DN, et al. Clinical review: Antiandrogens for the treatment of hirsutism: A systematic review and metaanalyses of randomized controlled trials. J Clin Endocrinol Metab. 2008;93:1153-1160.
61. Banaszewska B, Pawelczyk L, Spaczynski RZ, Duleba AJ. Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: Prospective randomized trial. J Clin Endocrinol Metab. 2009;94:4938-4945.
62. Sathyapalan T, Kilpatrick ES, Coady AM, Atkin SL. The effect of atorvastatin in patients with polycystic ovary syndrome: A randomized double-blind placebo-controlled study. J Clin Endocrinol Metab. 2009;94:103-108.
63. Sokalska A, Piotrowski PC, Rzepczynska IJ, Cress A, Duleba AJ. Statins inhibit growth of human theca-intersti-tial cells in PCOS and non-PCOS tissues independently of cholesterol availability. J Clin Endocrinol Metab. 2010;95: 5390-5394.
64. Banaszewska B, Pawelczyk L, Spaczynski RZ, Dziura J, Duleba AJ. Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: Prospective, random-ized, crossover trial. J Clin Endocrinol Metab. 2007;92: 456-461.
65. Moghetti P, Toscano V. Treatment of hirsutism and acne in hyperandrogenism. Best Pract Res Clin Endocrinol Metab. 2006;20:221-234.
66. Venturoli S, Marescalchi O, Colombo FM, et al. A pro-spective randomized trial comparing low dose flutamide, finasteride, ketoconazole, and cyproterone acetate-estrogen regimens in the treatment of hirsutism. J Clin Endocrinol Metab. 1999;84:1304-1310.
67. Wysowski DK, Fourcroy JL. Flutamide hepatotoxicity. J Urol. 1996;155:209-212.
68. Andrade RJ, Lucena MI, Fernández MC, et al. Fulminant liver failure associated with flutamide therapy for hirsutism. Lancet. 1999;353:983.
69. Rowan JA, Hague WM, Gao W, Battin MR, Moore MP; MiG Trial Investigators. Metformin versus insulin for the treatment of gestational diabetes. N Engl J Med. 2008;358: 2003-2015.
70. Vanky E, Stridsklev S, Heimstad R, et al. Metformin versus placebo from first trimester to delivery in polycys-tic ovary syndrome: A randomized, controlled multicenter study. J Clin Endocrinol Metab. 2010;95:E448-E455.